By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics reported after the close of the market Tuesday that its first-quarter 2012 revenues increased 20 percent, as it beat Wall Street estimates on both the top and bottom line.

The Salt Lake City-based molecular diagnostics firm brought in total revenues of $110.5 million for the three months ended Sept. 30, up from $91.9 million for the first quarter of 2011. Analysts had expected revenues of $106.5 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.